ABBV-744

1 1

Selleck Chemicals

S8723-2MG

€144,00 EUR
€144,00 EUR
Sale Sold out
Taxes included. Shipping calculated at checkout.
Size
View full details

ABBV-744 is an inhibitor of BET used in studies of Epigenetic Regulation. In practice, this places the compound in experiments that measure chromatin-state control, histone modification, and transcriptional regulation in cancer and epigenetics models.

By inhibiting BET, ABBV-744 can be used to examine chromatin-state control, histone modification, and transcriptional regulation. The epigenetic regulator annotation adds relevance to chromatin, epigenetic, and gene-expression profiling, together with downstream-response mapping in the same experimental setting. In cancer and epigenetics models, these readouts can be combined with viability, reporter, localization, biochemical conversion, or morphology endpoints to refine experimental interpretation.

Research Applications

  • Target-focused assays involving BET
  • Pathway perturbation studies connected to Epigenetic Regulation
  • Concentration-response inhibition and target-dependence studies
  • Chromatin, epigenetic, and gene-expression profiling

Overall, ABBV-744 is appropriate when a defined chemical perturbant is needed to connect BET with measurable biochemical, transcriptional, electrophysiological, imaging, or phenotypic readouts in cancer and epigenetics models. This profile is suited to mechanistic follow-up, comparative profiling, and assay optimization under defined exposure conditions.

Targets:
BET
Target Class:
Epigenetic Regulator
Pathways:
Epigenetic Regulation
Research Area:
Cancer • Epigenetics
CAS No.:
2138861-99-9
Molecular Weight:
491.55
Formula:
C₂₈H₃₀FN₃O₄
SMILES:
CCNC(=O)C1=CC2=C(N1)C(=O)N(C=C2C3=C(C=CC(=C3)C(C)(C)O)OC4=C(C=C(C=C4C)F)C)C
Storage Temperature:
-20°C

For Research Use Only. Not intended for diagnostic or therapeutic use.
Products may be subject to intellectual property rights.

The purchase of this product does not grant any license for commercial use, manufacturing, or clinical applications. The user is responsible for ensuring compliance with applicable laws and third-party rights.